Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2416491 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
N Engl J Med
March 2025
Natera, San Carlos, CA.
Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
N Engl J Med
March 2025
KU Leuven, Leuven, Belgium.
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study.
Breast Cancer Res
March 2025
Centre for Experimental Cancer Medicine, Barts Cancer Institute, London, UK.
Background: The multicohort, open-label, phase 1b KEYNOTE-173 study was conducted to investigate pembrolizumab plus chemotherapy as neoadjuvant therapy for triple-negative breast cancer (TNBC). This exploratory analysis evaluated features of the tumor microenvironment that might be predictive of response.
Methods: Cell fractions from 20 paired samples collected at baseline and after one cycle of neoadjuvant pembrolizumab prior to chemotherapy initiation were analyzed by spatial localization (tumor compartment, stromal compartment, or sum of tumor and stromal compartments [total tumor]) using three six-plex immunohistochemistry panels with T-cell, myeloid cell, and natural killer cell components.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!